KETAMIND

Repeat Ketamine Infusions Found to Have Cumulative, Sustained Antidepressant Effects "Repeat infusions of ketamine, starting thrice weekly then transitioning to once weekly, elicit a cumulative and sustained antidepressant response in patients with treatment-resistant depression, reports a study in AJP in Advance. This three-phase study also provides some of the first data to directly compare the response rates of single versus repeated infusions of ketamine, which will help inform clinical practice." http://alert.psychnews.org//repeat-ketamine-infusions-foun

Provocative new insight into how ketamine exerts its rapid anti-depressant effects | NEWATLAS.COM "It's been known for some time that ketamine blocks a protein receptor in the brain called N-methyl-D-aspartate (NMDA), and it is this process that many have suspected is the cause of the drug's fast-acting anti-depressant qualities. However, a growing body of research is beginning to suggest this hypothesis is overly simplistic, and even potentially wrong." https://newatlas.com/ketamine-metabolite-mechanism-antid//

"The nasal-spray form of the mind-altering drug will be available to patients as early as this week in select DEA-approved clinics. Some research shows that the drug, which produces an out-of-body, sedate feeling, can lessen the severity of depression when coupled with other antidepressant medication." https://nypost.com//this-party-drug-is-a-breakthrough-in-/

A new drug based on ketamine could help treat depression | ECONOMIST.COM https://www.economist.com//a-new-drug-based-on-ketamine-co

Esketamine Faces Challenges In Its Quest To Be A Breakthrough Drug Against Suicidal Ideation | FORBES.COM "But, the drug faces several significant clinical as well as economic challenges. The FDA approval process is invariably a balancing act, weighing safety and efficacy while attempting to get potentially life-saving drugs like esketamine to the marketplace as soon as possible. Three Phase III studies which the sponsor Janssen submitted as part of esketamine's New Drug Appl...ication showed "statistically significant, clinically meaningful rapid reduction of depressive symptoms as compared to placebo." One of the Phase III studies, however, failed to demonstrate statistically significant clinical change. Now that the drug is entering the market clinicians will soon learn about the drug's real-world effectiveness, but also long-term effects. Concerns have been raised about potentially serious side-effects and the current lack of long-term data on esketamine's health impact." https://www.forbes.com//esketamine-faces-challenges-in-i/